CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15 th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15 th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf= Astoria in New York City.
Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs on Monday, February 11, 2013 at 11:00 a.m. ET.
Palatin Technologies has reported positive top-line results in its recently completed Phase 2B clinical trial with bremelanotide for treatment of female sexual dysfunction, and is preparing for an end-of-Phase 2 meeting with the Food and Drug Administration in anticipation of commencing Phase 3 trials. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through February 18, 2013.
About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.ABOUT THE BIO CEO & INVESTOR CONFERENCE The 15 th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber private companies will be presenting at the event, and plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors and can be accessed here: http://www.bio.org/events/conferences/bio-ceo-investor-registration. SOURCE Palatin Technologies, Inc.